How Does Clinuvel Pharmaceuticals(ASX:CUV) Plan to Expand Its Product Portfolio with NEURACTHEL in Europe?

Sonal Goyal

05 November 2026 06:16 PM AEDT

How Does Clinuvel Pharmaceuticals(ASX:CUV) Plan to Expand Its Product Portfolio with NEURACTHEL in Europe?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Clinuvel filed NEURACTHEL Instant for Marketing authorisation with European regulators via the decentralised procedure on 30 October 2026

• The global ACTH market is estimated at US$1.3 billion annually, representing a significant commercial opportunity for Clinuvel's second product

• Shares of Clinuvel closed at A$7.74 on 05 November 2026, gaining 9.32% in a session where the S&P/ASX 200 Health Care index advanced 3.64%

Clinuvel Pharmaceuticals(ASX:CUV) closed at A$7.74 on 05 November 2026, marking a 9.32% gain that outpaced the broader market. The S&P/ASX 200 (XJO) advanced 2.61%, adding 230.60 points to close at 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) climbed 3.64%, gaining 1,240.30 points to reach 35,329.10. Overnight gains on Wall Street following the Democrats' decisive victory in the U.S. midterm elections provided a favourable backdrop for equities globally. Clinuvel is a global biopharmaceutical company focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders, with its portfolio centred on melanocortin peptides.

NEURACTHEL European Filing Marks Key Milestone

On 30 October 2026, Clinuvel announced it had filed a dossier for the marketing authorisation of NEURACTHEL Instant (tetracosactide) with national European regulators through the European decentralised procedure (DCP). NEURACTHEL Instant is the company's branded generic formulation of tetracosactide, a synthetic 24-amino acid peptide analogue of naturally occurring adrenocorticotropic hormone (ACTH). If approved, Clinuvel would be able to commercialise the product as a prescription pharmaceutical in up to three initial EU Member States.

ACTH products are approved systemically in the United States for 19 conditions, including infantile spasms and acute exacerbations of multiple sclerosis. In Europe, ACTH products serve as both a therapy and a diagnostic tool for adrenal insufficiency. The global ACTH market is currently estimated at US$1.3 billion annually.

Clinuvel has identified three EU Member States as initial launch markets based on prescriber demand, pricing infrastructure, reported ACTH shortages, and overlap with existing distribution of its lead product SCENESSE. The DCP regulatory review is intended to take 300 days excluding potential clock-stop periods, with initial feedback expected in approximately four months.

Commercial Strategy and Further Expansion

Dr Dennis Wright, Clinuvel's Chief Scientific Officer, noted that the company had identified what it believes to be optimal launch markets based on a range of commercial and practical factors. Additional submissions to the UK's MHRA and other EU Member States are being evaluated, while a timeline for filing with the U.S. FDA is under review. NEURACTHEL Instant is not currently approved in any country.

About Clinuvel Pharmaceuticals

Clinuvel is a global biopharmaceutical company listed on both the ASX and Nasdaq. The company's lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Canada, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). With NEURACTHEL, Clinuvel is expanding beyond its single-product portfolio into the broader melanocortin peptide space.

Sector Context

The healthcare sector on the ASX experienced a broad-based rally on 05 November 2026, with the XHJ index gaining 3.64%. Biopharmaceutical companies with pipeline catalysts and product expansion narratives attracted particular attention as global Equity markets benefited from the overnight Wall Street gains. Clinuvel's outperformance of both the broader ASX 200 and the healthcare sub-index reflects the market's reception of its European regulatory filing.

Risks to Consider

Key risks for Clinuvel include the regulatory uncertainty surrounding NEURACTHEL's approval timeline, as the DCP process may involve clock stops that extend the review period. Competition in the global ACTH market from established generics manufacturers could pressure pricing and market share. The company's Revenue base remains concentrated in SCENESSE, and any setback to NEURACTHEL's approval could delay portfolio diversification. Currency exposure across multiple jurisdictions also adds Earnings variability.

Catalysts on Watch

Investors will be monitoring the initial regulatory feedback on the NEURACTHEL filing, expected in approximately four months. Additional filings with the UK's MHRA and other EU nations could expand the product's addressable market. Further commercialisation of SCENESSE across existing markets and any updates on the U.S. FDA submission timeline for NEURACTHEL represent additional milestones to watch.

The Road Ahead

Clinuvel's filing of NEURACTHEL Instant in Europe represents a meaningful step toward becoming a multi-product biopharmaceutical company. The US$1.3 billion global ACTH market presents a sizeable commercial opportunity, though the 300-day-plus regulatory review timeline means meaningful revenue contributions from the product remain some distance away. The company's ability to Leverage its existing European distribution infrastructure for SCENESSE could provide a cost-efficient pathway to market if approval is secured.

FAQs

Q: What is NEURACTHEL Instant and why is Clinuvel filing it in Europe?

A: NEURACTHEL Instant is Clinuvel's branded generic formulation of tetracosactide, a synthetic analogue of adrenocorticotropic hormone (ACTH). The company filed for marketing authorisation in Europe to address prescriber demand and reported shortages of ACTH products in key EU markets.

Q: How large is the global ACTH market?

A: The global ACTH market is currently estimated at approximately US$1.3 billion annually. ACTH products are approved in the U.S. for 19 conditions and used in Europe as both a therapy and a diagnostic tool.

Q: What is the expected timeline for the European regulatory review?

A: The European decentralised procedure is intended to take 300 days excluding potential clock-stop periods. Initial feedback from the reference Member State is expected in approximately four months from filing.

Q: What is Clinuvel's other approved product?

A: Clinuvel's lead product is SCENESSE (afamelanotide 16mg), approved in Europe, the USA, Canada, Israel, and Australia as the world's first systemic photoprotective drug for adult patients with erythropoietic protoporphyria (EPP).

Q: Is NEURACTHEL Instant approved in any country currently?

A: No. NEURACTHEL Instant is not currently approved in any country. The European filing represents its first submission to a regulatory authority.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.